Molecular fingerprints of cardiovascular toxicities of immune checkpoint inhibitors

https://m2.mtmt.hu/ eng 2026-04-15 11:20 JournalArticle 35140697 VALIDATED true Export Date: 09 April 2025; Cited By: 5; CODEN: BRCAB 0 false 2026-04-14T08:38:37.385+0000 2026-02-24T12:55:37.787+0000 2024-07-21T15:35:04.941+0000 true 10026589 Tichy Rita /api/admin/10026589 Admin Rita Tichy (SE_KK_Admin5_TR, admin) true 10026589 2026-03-27T10:20:58.857+0000 2026-03-27T10:20:58.857+0000 2025-04-03T12:13:58.975+0000 true 10062062 Gere Tamásné /api/admin/10062062 Admin Tamásné Gere (SE_KK_Admin5_GT, admin) true 10062062 true false true 24 24 /api/publicationtype/24 PublicationType Journal Article 1 true 24 JournalArticle true 1134514 Survey paper true 24 24 /api/publicationtype/24 PublicationType Journal Article 1 true 24 JournalArticle /api/subtype/1134514 Összefoglaló cikk SubType Survey paper (Journal Article) 102 true 1134514 true 1 /api/category/1 Category Scientific true 1 Gergely, Tamás G. Molecular fingerprints of cardiovascular toxicities of immune checkpoint inhibitors true true /api/journal/656 REVIEWED BASIC RESEARCH IN CARDIOLOGY 0300-8428 1435-1803 true false 656 false 656 true 0300-8428 1435-1803 Journal FOREIGN 120 1 187 205 187 19 2025 Immune checkpoint inhibitors (ICIs) have revolutionized cancer therapy by unleashing the power of the immune system against malignant cells. However, their use is associated with a spectrum of adverse effects, including cardiovascular complications, which can pose significant clinical challenges. Several mechanisms contribute to cardiovascular toxicity associated with ICIs. First, the dysregulation of immune checkpoints, such as cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) and programmed cell death protein-1 (PD-1) and its ligand (PD-L1), and molecular mimicry with cardiac autoantigens, leads to immune-related adverse events, including myocarditis and vasculitis. These events result from the aberrant activation of T cells against self-antigens within the myocardium or vascular endothelium. Second, the disruption of immune homeostasis by ICIs can lead to autoimmune-mediated inflammation of cardiac tissues, manifesting as cardiac dysfunction and heart failure, arrhythmias, or pericarditis. Furthermore, the upregulation of inflammatory cytokines, particularly tumor necrosis factor-alpha, interferon-γ, interleukin-1β, interleukin-6, and interleukin-17 contributes to cardiac and endothelial dysfunction, plaque destabilization, and thrombosis, exacerbating cardiovascular risk on the long term. Understanding the intricate mechanisms of cardiovascular side effects induced by ICIs is crucial for optimizing patient care and to ensure the safe and effective integration of immunotherapy into a broader range of cancer treatment protocols. The clinical implications of these mechanisms underscore the importance of vigilant monitoring and early detection of cardiovascular toxicity in patients receiving ICIs. Future use of these key pathological mediators as biomarkers may aid in prompt diagnosis of cardiotoxicity and will allow timely interventions. Funding 2042518 /api/funding/2042518 (Open access funding provided by Semmelweis University) false true Funding 2042519 /api/funding/2042519 HCEMM(HCEMM No. 739593) Funder: Horizon 2020 false true Funding 2042520 /api/funding/2042520 (LP-2021-14) false true Funding 2042521 /api/funding/2042521 (RRF-2.3.1-21-2022-00003) false true Funding 2042522 /api/funding/2042522 (2022-1.1.1-KK-2022-00005) false true Funding 2042523 /api/funding/2042523 Az orvos-, egészségtudományi- és gyógyszerészképzés tudományos műhelyeinek fejlesztése(EFOP-3.6.3-VEKOP-16-2017-00009) Funder: EFOP-VEKOP false true Funding 2042524 /api/funding/2042524 (Semmelweis 250+ Excellence Scholarship) false true Funding 2042525 /api/funding/2042525 Richter Gedeon Talentum Foundation false true Funding 2042526 /api/funding/2042526 (ÚNKP-22-4-II-SE) false true Funding 2042527 /api/funding/2042527 (ÚNKP-23-II-SE-43) false true true 2024 true true true false true false GOLD 2026-04-14 true https://doi.org/10.1007/s00395-024-01068-8 32 0 32 31 0 32 32 31 29 32 32 31 31 31 1 0 32 31 32 31 0 9 9 Folyóiratcikk Journal Article 24 32 Könyvrészlet Chapter in Book 25 0 Könyv Book 23 0 Egyéb konferenciaközlemény Conference paper 31 0 Egyéb konferenciakötet Conference proceedings 32 0 Oltalmi formák Protection forms 26 0 Disszertáció Thesis 28 0 Egyéb Miscellaneous 29 0 Alkotás Achievement 22 0 Kutatási adat Research data 33 0 Folyóiratcikk Journal Article 24 0 0 0 Könyvrészlet Chapter in Book 25 0 0 0 Könyv Book 23 0 0 0 Egyéb konferenciaközlemény Conference paper 31 0 0 0 Egyéb konferenciakötet Conference proceedings 32 0 0 0 Oltalmi formák Protection forms 26 0 0 0 Disszertáció Thesis 28 0 0 0 Egyéb Miscellaneous 29 0 0 0 Alkotás Achievement 22 0 0 0 Kutatási adat Research data 33 0 0 0 2024 0 1 1 1 1 2025 0 23 23 23 23 2026 0 8 7 8 7 D1 false 10074629,10028393 false false false 2024-10-19T15:43:04.872+0000 Farmakológiai és Farmakoterápiás Intézet (SE / AOK / I); Farmakológiai és Gyógyszerkutatás-fejlesztési K... (SE / KSZE); HCEMM-SE Kardiometabolikus Immunológia Kutatócs... (SE / AOK / I / FFI); Kardiológia Központ - Kardiológiai Tanszék (SE / AOK / K); MTA-SE Momentum Kardio-Onkológia és Kardioimmun... (SE / AOK / I / FFI); Városmajori Szív- és Érgyógyászati Klinika (SE / AOK / K) 5 29 6 5 0 true Language 10002 /api/language/10002 English Angol English true 2 true PersonAuthorship 118388513 /api/authorship/118388513 Gergely, Tamás G. [Gergely, Tamás G (kardiovaszkuláris...), author] Department of Pharmacology and Pharmacotherapy (SU / FM / I); HCEMM-SU Cardiometabolic Immunology Research Group (SU / FM / I / DPP); MTA-SE Momentum Cardio-Oncology and Cardioimmun... (SU / FM / I / DPP); Centre for Pharmacology and Pharmaceutical Rese... (SU / KSZE) 1 0.2 true false false Author 10074629 /api/author/10074629 Tamás G Gergely (kardiovaszkuláris farmakológia) Gergely Tamás G true true Gergely Tamás G. true false false AuthorshipType 1 /api/authorshiptype/1 Author 0 true 0 true false true PersonAuthorship 118388514 /api/authorship/118388514 Drobni, Zsófia D. [Drobni, Zsófia (kardiológia), author] Cardiovascular Center (SU / FM / C); Department of Cardiology – Heart and Vascular C... (SU / FM / C) 2 0.2 false false false Author 10061268 /api/author/10061268 Zsófia Drobni (kardiológia) Drobni Zsófia true 10061268 true Drobni Zsófia D. true false false AuthorshipType 1 /api/authorshiptype/1 Author 0 true 0 true false true PersonAuthorship 118388515 /api/authorship/118388515 Sayour, Nabil V. [Sayour, Viktor Nabil (farmakológia), author] Department of Pharmacology and Pharmacotherapy (SU / FM / I); HCEMM-SU Cardiometabolic Immunology Research Group (SU / FM / I / DPP); MTA-SE Momentum Cardio-Oncology and Cardioimmun... (SU / FM / I / DPP); Centre for Pharmacology and Pharmaceutical Rese... (SU / KSZE) 3 0.2 false false false Author 10074459 /api/author/10074459 Viktor Nabil Sayour (farmakológia) Sayour Viktor Nabil true true Sayour Nabil V. true false false AuthorshipType 1 /api/authorshiptype/1 Author 0 true 0 true false true PersonAuthorship 118388516 /api/authorship/118388516 Ferdinandy, Péter [Ferdinandy, Péter (Farmakológia, mol...), author] Department of Pharmacology and Pharmacotherapy (SU / FM / I); Centre for Pharmacology and Pharmaceutical Rese... (SU / KSZE) 4 0.2 false false false Author 10010125 /api/author/10010125 Péter Ferdinandy (Farmakológia, molekuláris medicina) Ferdinandy Péter true 10010125 true Ferdinandy Péter true false false AuthorshipType 1 /api/authorshiptype/1 Author 0 true 0 true false true PersonAuthorship 118388517 /api/authorship/118388517 Varga, Zoltán V. ✉ [Varga, Zoltán (kardiovaszkuláris...), author] Department of Pharmacology and Pharmacotherapy (SU / FM / I); HCEMM-SU Cardiometabolic Immunology Research Group (SU / FM / I / DPP); MTA-SE Momentum Cardio-Oncology and Cardioimmun... (SU / FM / I / DPP); Centre for Pharmacology and Pharmaceutical Rese... (SU / KSZE) 5 0.2 false true true Author 10028393 /api/author/10028393 Zoltán Varga (kardiovaszkuláris kutatás) Varga Zoltán true 10028393 true Varga Zoltán V. true false false AuthorshipType 1 /api/authorshiptype/1 Author 0 true 0 true false true PublicationIdentifier 26851582 /api/publicationidentifier/26851582 DOI: 10.1007/s00395-024-01068-8 PlainSource 6 /api/publicationsource/6 DOI PublicationSourceType 10001 /api/publicationsourcetype/10001 DOI true true true DOI DOI https://doi.org/@@@ true true 6 true GOLD true IDENTICAL 10.1007/s00395-024-01068-8 https://doi.org/10.1007/s00395-024-01068-8 false true PublicationIdentifier 26883183 /api/publicationidentifier/26883183 WoS: 001271499300001 PlainSource 1 /api/publicationsource/1 WoS PublicationSourceType 10003 /api/publicationsourcetype/10003 Indexelő adatbázis false true true WoS WoS https://www.webofscience.com/wos/woscc/full-record/@@@ true true 1 true IDENTICAL 001271499300001 https://www.webofscience.com/wos/woscc/full-record/001271499300001 true true PublicationIdentifier 26870312 /api/publicationidentifier/26870312 Scopus: 85198939587 PlainSource 3 /api/publicationsource/3 Scopus PublicationSourceType 10003 /api/publicationsourcetype/10003 Indexelő adatbázis false true true Scopus Scopus http://www.scopus.com/record/display.url?origin=inward&eid=2-s2.0-@@@ true true 3 true IDENTICAL 85198939587 http://www.scopus.com/record/display.url?origin=inward&eid=2-s2.0-85198939587 true true PublicationIdentifier 26851583 /api/publicationidentifier/26851583 PubMed: 39023770 PlainSource 17 /api/publicationsource/17 PubMed PublicationSourceType 10003 /api/publicationsourcetype/10003 Indexelő adatbázis false true true PubMed PubMed http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=@@@&dopt=Abstract true true 17 true IDENTICAL 39023770 http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=39023770&dopt=Abstract false true PublicationIdentifier 29921753 /api/publicationidentifier/29921753 Other URL: https://www.scopus.com/inward/record.uri?eid=2-s2.0-85198939587&doi=10.1007%2Fs00395-024-01068-8&partnerID=40&md5=cd8fad35ee84a0cdbb8d5e6799041fca PlainSource 40 /api/publicationsource/40 Other URL PublicationSourceType 10006 /api/publicationsourcetype/10006 Link true true true Egyéb URL Other URL @@@ true true 40 true NONE IDENTICAL https://www.scopus.com/inward/record.uri?eid=2-s2.0-85198939587&doi=10.1007%2Fs00395-024-01068-8&partnerID=40&md5=cd8fad35ee84a0cdbb8d5e6799041fca https://www.scopus.com/inward/record.uri?eid=2-s2.0-85198939587&doi=10.1007%2Fs00395-024-01068-8&partnerID=40&md5=cd8fad35ee84a0cdbb8d5e6799041fca false true PublicationIdentifier 31528660 /api/publicationidentifier/31528660 Other URL: https://link.springer.com/10.1007/s00395-024-01068-8 PlainSource 40 /api/publicationsource/40 Other URL PublicationSourceType 10006 /api/publicationsourcetype/10006 Link true true true Egyéb URL Other URL @@@ true true 40 true IDENTICAL https://link.springer.com/10.1007/s00395-024-01068-8 https://link.springer.com/10.1007/s00395-024-01068-8 false true SjrRating 11563273 /api/sjrrating/11563273 sjr:D1 (2025) Scopus - Cardiology and Cardiovascular Medicine BASIC RESEARCH IN CARDIOLOGY 0300-8428 1435-1803 22 0.1 journal RatingType 10002 /api/ratingtype/10002 sjr sjr true true ClassificationExternal 2705 /api/classificationexternal/2705 Scopus - Cardiology and Cardiovascular Medicine true 2705 true D1 FROM_LAST_YEAR true true Reference 55893577 /api/reference/55893577 1. Advani R, Flinn I, Popplewell L, Forero A, Bartlett NL, Ghosh N, Kline J, Roschewski M, LaCasce A, Collins GP, Tran T, Lynn J, Chen JY, Volkmer J-P, Agoram B, Huang J, Majeti R, Weissman IL, Takimoto CH, Chao MP, Smith SM (2018) CD47 blockade by Hu5F9-G4 and rituximab in non-hodgkin’s lymphoma. N Engl J Med 379:1711–1721. https://doi.org/10.1056/nejmoa1807315, DOI: 10.1056/nejmoa1807315 1 10.1056/nejmoa1807315 false true Reference 55893578 /api/reference/55893578 2. Ait-Oufella H, Salomon BL, Potteaux S, Robertson AKL, Gourdy P, Zoll J, Merval R, Esposito B, Cohen JL, Fisson S, Flavell RA, Hansson GK, Klatzmann D, Tedgui A, Mallat Z (2006) Natural regulatory T cells control the development of atherosclerosis in mice. Nat Med 12:178–180. https://doi.org/10.1038/nm1343, DOI: 10.1038/nm1343 2 10.1038/nm1343 false true Reference 55893579 /api/reference/55893579 3. Alhumaid W, Yogasundaram H, Senaratne JM (2021) Slow bidirectional ventricular tachycardia as a manifestation of immune checkpoint inhibitor myocarditis. Eur Heart J 42:2868. https://doi.org/10.1093/eurheartj/ehab219, DOI: 10.1093/eurheartj/ehab219 3 10.1093/eurheartj/ehab219 false true Reference 55893580 /api/reference/55893580 4. Ali A, Caldwell R, Pina G, Beinart N, Jensen G, Yusuf SW, Koutroumpakis E, Hamzeh I, Khalaf S, Iliescu C, Deswal A, Palaskas NL (2024) Elevated IL-6 and tumor necrosis factor-α in immune checkpoint inhibitor myocarditis. Diseases 12:1–11. https://doi.org/10.3390/diseases12050088, DOI: 10.3390/diseases12050088 4 10.3390/diseases12050088 false true Reference 55893581 /api/reference/55893581 5. Allenbach Y, Anquetil C, Manouchehri A, Benveniste O, Lambotte O, Lebrun-Vignes B, Spano JP, Ederhy S, Klatzmann D, Rosenzwajg M, Fautrel B, Cadranel J, Johnson DB, Moslehi JJ, Salem JE (2020) Immune checkpoint inhibitor-induced myositis, the earliest and most lethal complication among rheumatic and musculoskeletal toxicities. Autoimmun Rev 19:102586. https://doi.org/10.1016/j.autrev.2020.102586, DOI: 10.1016/j.autrev.2020.102586 5 10.1016/j.autrev.2020.102586 false true Reference 55893582 /api/reference/55893582 6. Altan M, Toki MI, Gettinger SN, Carvajal-Hausdorf DE, Zugazagoitia J, Sinard JH, Herbst RS, Rimm DL (2019) Immune checkpoint inhibitor-associated pericarditis. J Thorac Oncol 14:1102–1108. https://doi.org/10.1016/j.jtho.2019.02.026, DOI: 10.1016/j.jtho.2019.02.026 6 10.1016/j.jtho.2019.02.026 false true Reference 55893583 /api/reference/55893583 7. Amiri-Kordestani L, Moslehi J, Cheng J, Tang S, Schroeder R, Sridhara R, Karg K, Connolly J, Beaver JA, Blumenthal GM, Pazdur R (2018) Cardiovascular adverse events in immune checkpoint inhibitor clinical trials: a U.S. Food and drug administration pooled analysis. J Clin Oncol 36:3009. https://doi.org/10.1200/JCO.2018.36.15_suppl.3009, DOI: 10.1200/JCO.2018.36.15_suppl.3009 7 10.1200/JCO.2018.36.15_suppl.3009 false true Reference 55893584 /api/reference/55893584 8. Axelrod ML, Meijers WC, Screever EM, Qin J, Carroll MG, Sun X, Tannous E, Zhang Y, Sugiura A, Taylor BC, Hanna A, Zhang S, Amancherla K, Tai W, Wright JJ, Wei SC, Opalenik SR, Toren AL, Rathmell JC, Ferrell PB, Phillips EJ, Mallal S, Johnson DB, Allison JP, Moslehi JJ, Balko JM (2022) T cells specific for α-myosin drive immunotherapy-related myocarditis. Nature. https://doi.org/10.1038/s41586-022-05432-3, DOI: 10.1038/s41586-022-05432-3 8 10.1038/s41586-022-05432-3 false true Reference 55893585 /api/reference/55893585 9. Ball S, Ghosh RK, Wongsaengsak S, Bandyopadhyay D, Ghosh GC, Aronow WS, Fonarow GC, Lenihan DJ, Bhatt DL (2019) Cardiovascular toxicities of immune checkpoint inhibitors: JACC review topic of the week. j am coll cardiol 74:1714–1727. https://doi.org/10.1016/j.jacc.2019.07.079, DOI: 10.1016/j.jacc.2019.07.079 9 10.1016/j.jacc.2019.07.079 false true Reference 55893586 /api/reference/55893586 10. Barrett TJ (2020) Macrophages in atherosclerosis regression. Arterioscler Thromb Vasc Biol 40:20–33. https://doi.org/10.1161/ATVBAHA.119.312802, DOI: 10.1161/ATVBAHA.119.312802 10 10.1161/ATVBAHA.119.312802 false true Reference 55893587 /api/reference/55893587 11. Boesten LSM, Zadelaar ASM, Van Nieuwkoop A, Gijbels MJJ, De Winther MPJ, Havekes LM, Van Vlijmen BJM (2005) Tumor necrosis factor-α promotes atherosclerotic lesion progression in APOE*3-leiden transgenic mice. Cardiovasc Res 66:179–185. https://doi.org/10.1016/j.cardiores.2005.01.001, DOI: 10.1016/j.cardiores.2005.01.001 11 10.1016/j.cardiores.2005.01.001 false true Reference 55893588 /api/reference/55893588 12. Boland P, Heath J, Sandigursky S (2020) Immune checkpoint inhibitors and vasculitis. Curr Opin Rheumatol 32:53–56. https://doi.org/10.1097/BOR.0000000000000672, DOI: 10.1097/BOR.0000000000000672 12 10.1097/BOR.0000000000000672 false true Reference 55893589 /api/reference/55893589 13. Bu DX, Tarrio M, Maganto-Garcia E, Stavrakis G, Tajima G, Lederer J, Jarolim P, Freeman GJ, Sharpe AH, Lichtman AH (2011) Impairment of the programmed cell death-1 pathway increases atherosclerotic lesion development and inflammation. Arterioscler Thromb Vasc Biol 31:1100–1107. https://doi.org/10.1161/ATVBAHA.111.224709, DOI: 10.1161/ATVBAHA.111.224709 13 10.1161/ATVBAHA.111.224709 false true Reference 55893590 /api/reference/55893590 14. Bukamur HS, Mezughi H, Karem E, Shahoub I, Shweihat Y (2019) Nivolumab-induced third degree atrioventricular block in a patient with stage IV squamous cell lung carcinoma. Cureus 11:10–13. https://doi.org/10.7759/cureus.4869, DOI: 10.7759/cureus.4869 14 10.7759/cureus.4869 false true Reference 55893591 /api/reference/55893591 15. Cadena RH, Abdulahad WH, Hospers GAP, Wind TT, Boots AMH, Heeringa P, Brouwer E (2018) Checks and balances in autoimmune vasculitis. Front Immunol 9:1–11. https://doi.org/10.3389/fimmu.2018.00315, DOI: 10.3389/fimmu.2018.00315 15 10.3389/fimmu.2018.00315 false true Reference 55893592 /api/reference/55893592 16. Calabretta R, Hoeller C, Pichler V, Mitterhauser M, Karanikas G, Haug A, Li X, Hacker M (2020) Immune checkpoint inhibitor therapy induces inflammatory activity in large arteries. Circulation 142:2396–2398. https://doi.org/10.1161/CIRCULATIONAHA.120.048708, DOI: 10.1161/CIRCULATIONAHA.120.048708 16 10.1161/CIRCULATIONAHA.120.048708 false true Reference 55893593 /api/reference/55893593 17. Champion SN, Stone JR (2020) Immune checkpoint inhibitor associated myocarditis occurs in both high-grade and low-grade forms. Mod Pathol 33:99–108. https://doi.org/10.1038/s41379-019-0363-0, DOI: 10.1038/s41379-019-0363-0 17 10.1038/s41379-019-0363-0 false true Reference 55893594 /api/reference/55893594 18. Chen YH, Kovács T, Ferdinandy P, Varga ZV (2024) Treatment options for immune-related adverse events associated with immune checkpoint inhibitors. Br J Pharmacol. https://doi.org/10.1111/bph.16405, DOI: 10.1111/bph.16405 18 10.1111/bph.16405 false true Reference 55893595 /api/reference/55893595 19. Cheniti G, Vlachos K, Pambrun T, Hooks D, Frontera A, Takigawa M, Bourier F, Kitamura T, Lam A, Martin C, Dumas-Pommier C, Puyo S, Pillois X, Duchateau J, Klotz N, Denis A, Derval N, Jais P, Cochet H, Hocini M, Haissaguerre M, Sacher F (2018) Atrial fibrillation mechanisms and implications for catheter ablation. Front Physiol 9:1–24. https://doi.org/10.3389/fphys.2018.01458, DOI: 10.3389/fphys.2018.01458 19 10.3389/fphys.2018.01458 false true Reference 55893596 /api/reference/55893596 20. Cochain C, Chaudhari SM, Koch M, Wiendl H, Eckstein H-H, Zernecke A (2014) Programmed cell death-1 deficiency exacerbates T cell activation and atherogenesis despite expansion of regulatory T cells in atherosclerosis-prone mice. PLoS ONE 9:e93280, DOI: 10.1371/journal.pone.0093280 20 10.1371/journal.pone.0093280 false true Reference 55893597 /api/reference/55893597 21. Cochain C, Vafadarnejad E, Arampatzi P, Pelisek J, Winkels H, Ley K, Wolf D, Saliba AE, Zernecke A (2018) Single-cell RNA-seq reveals the transcriptional landscape and heterogeneity of aortic macrophages in murine atherosclerosis. Circ Res 122:1661–1674. https://doi.org/10.1161/CIRCRESAHA.117.312509, DOI: 10.1161/CIRCRESAHA.117.312509 21 10.1161/CIRCRESAHA.117.312509 false true Reference 55893598 /api/reference/55893598 22. Cole JE, Park I, Ahern DJ, Kassiteridi C, Abeam DD, Goddard ME, Green P, Maffia P, Monaco C (2018) Immune cell census in murine atherosclerosis: cytometry by time of flight illuminates vascular myeloid cell diversity. Cardiovasc Res 114:1360–1371. https://doi.org/10.1093/cvr/cvy109, DOI: 10.1093/cvr/cvy109 22 10.1093/cvr/cvy109 false true Reference 55893599 /api/reference/55893599 23. Cuddy S, Payne DL, Murphy DJ, Dunne RM, Bueno R, Blankstein R, Di Carli M, Mehra MR, Nohria A, Groarke JD (2019) Incidental coronary artery calcification in cancer imaging. JACC CardioOncol 1:135–137. https://doi.org/10.1016/j.jaccao.2019.08.005, DOI: 10.1016/j.jaccao.2019.08.005 23 10.1016/j.jaccao.2019.08.005 false true Reference 55893600 /api/reference/55893600 24. Dietel B, Cicha I, Voskens CJ, Verhoeven E, Achenbach S, Garlichs CD (2013) Decreased numbers of regulatory T cells are associated with human atherosclerotic lesion vulnerability and inversely correlate with infiltrated mature dendritic cells. Atherosclerosis 230:92–99. https://doi.org/10.1016/j.atherosclerosis.2013.06.014, DOI: 10.1016/j.atherosclerosis.2013.06.014 24 10.1016/j.atherosclerosis.2013.06.014 false true Reference 55893601 /api/reference/55893601 25. Dolladille C, Akroun J, Morice PM, Dompmartin A, Ezine E, Sassier M, Da-Silva A, Plane AF, Legallois D, L’Orphelin JM, Alexandre J (2021) Cardiovascular immunotoxicities associated with immune checkpoint inhibitors: a safety meta-analysis. Eur Heart J 42:4964–4977. https://doi.org/10.1093/eurheartj/ehab618, DOI: 10.1093/eurheartj/ehab618 25 10.1093/eurheartj/ehab618 false true Reference 55893602 /api/reference/55893602 26. Dolladille C, Ederhy S, Allouche S, Dupas Q, Gervais R, Madelaine J, Sassier M, Plane AF, Comoz F, Cohen AA, Thuny FR, Cautela J, Alexandre J (2020) Late cardiac adverse events in patients with cancer treated with immune checkpoint inhibitors. J Immunother Cancer 8:1–10. https://doi.org/10.1136/jitc-2019-000261, DOI: 10.1136/jitc-2019-000261 26 10.1136/jitc-2019-000261 false true Reference 55893603 /api/reference/55893603 27. Drobni ZD, Alvi RM, Taron J, Zafar A, Murphy SP, Rambarat PK, Mosarla RC, Lee C, Zlotoff DA, Raghu VK, Hartmann SE, Gilman HK, Gong J, Zubiri L, Sullivan RJ, Reynolds KL, Mayrhofer T, Zhang L, Hoffmann U, Neilan TG (2020) Association between immune checkpoint inhibitors with cardiovascular events and atherosclerotic plaque. Circulation. https://doi.org/10.1161/CIRCULATIONAHA.120.049981, DOI: 10.1161/CIRCULATIONAHA.120.049981 27 10.1161/CIRCULATIONAHA.120.049981 false true Reference 55893604 /api/reference/55893604 28. Drobni ZD, Gongora C, Taron J, Suero-Abreu GA, Karady J, Gilman HK, Supraja S, Nikolaidou S, Leeper N, Merkely B, Maurovich-Horvat P, Foldyna B, Neilan TG (2023) Impact of immune checkpoint inhibitors on atherosclerosis progression in patients with lung cancer. J Immunother Cancer. https://doi.org/10.1136/jitc-2023-007307, DOI: 10.1136/jitc-2023-007307 28 10.1136/jitc-2023-007307 false true Reference 55893605 /api/reference/55893605 29. Drobni ZD, Zafar A, Zubiri L, Zlotoff DA, Alvi RM, Lee C, Hartmann S, Gilman HK, Villani AC, Nohria A, Groarke JD, Sullivan RJ, Reynolds KL, Zhang L, Neilan TG (2020) Decreased absolute lymphocyte count and increased neutrophil/lymphocyte ratio with immune checkpoint inhibitor–associated myocarditis. J Am Heart Assoc. https://doi.org/10.1161/JAHA.120.018306, DOI: 10.1161/JAHA.120.018306 29 10.1161/JAHA.120.018306 false true Reference 55893606 /api/reference/55893606 30. D’Souza M, Nielsen D, Svane IM, Iversen K, Rasmussen PV, Madelaire C, Fosbøl E, Køber L, Gustafsson F, Andersson C, Gislason G, Torp-Pedersen C, Schou M (2020) The risk of cardiac events in patients receiving immune checkpoint inhibitors: a nationwide Danish study. Eur Heart J. https://doi.org/10.1093/eurheartj/ehaa884, DOI: 10.1093/eurheartj/ehaa884 30 10.1093/eurheartj/ehaa884 false true Reference 55893607 /api/reference/55893607 31. Efentakis P, Choustoulaki A, Kwiatkowski G, Varela A, Kostopoulos IV, Tsekenis G, Ntanasis-Stathopoulos I, Georgoulis A, Vorgias CE, Gakiopoulou H, Briasoulis A, Davos CH, Kostomitsopoulos N, Tsitsilonis O, Dimopoulos MA, Terpos E, Chłopicki S, Gavriatopoulou M, Andreadou I (2024) Early microvascular coronary endothelial dysfunction precedes pembrolizumab-induced cardiotoxicity. Preventive role of high dose of atorvastatin. Basic Res Cardiol. https://doi.org/10.1007/s00395-024-01046-0, DOI: 10.1007/s00395-024-01046-0 31 10.1007/s00395-024-01046-0 false true Reference 55893608 /api/reference/55893608 32. Engelmann B, Massberg S (2013) Thrombosis as an intravascular effector of innate immunity. Nat Rev Immunol 13:34–45. https://doi.org/10.1038/nri3345, DOI: 10.1038/nri3345 32 10.1038/nri3345 false true Reference 55893609 /api/reference/55893609 33. Escudier M, Cautela J, Malissen N, Ancedy Y, Orabona M, Pinto J, Monestier S, Grob JJ, Scemama U, Jacquier A, Lalevee N, Barraud J, Peyrol M, Laine M, Bonello L, Paganelli F, Cohen A, Barlesi F, Ederhy S, Thuny F (2017) Clinical features, management, and outcomes of immune checkpoint inhibitor-related cardiotoxicity. Circulation 136:2085–2087. https://doi.org/10.1161/CIRCULATIONAHA.117.030571, DOI: 10.1161/CIRCULATIONAHA.117.030571 33 10.1161/CIRCULATIONAHA.117.030571 false true Reference 55893610 /api/reference/55893610 34. Ewing MM, Karper JC, Abdul S, De Jong RCM, Peters HAB, De Vries MR, Redeker A, Kuiper J, Toes REM, Arens R, Jukema JW, Quax PHA (2013) T-cell co-stimulation by CD28-CD80/86 and its negative regulator CTLA-4 strongly influence accelerated atherosclerosis development. Int J Cardiol 168:1965–1974. https://doi.org/10.1016/j.ijcard.2012.12.085, DOI: 10.1016/j.ijcard.2012.12.085 34 10.1016/j.ijcard.2012.12.085 false true Reference 55893611 /api/reference/55893611 35. Fenioux C, Abbar B, Boussouar S, Bretagne M, Power JR, Moslehi JJ, Gougis P, Amelin D, Dechartres A, Lehmann LH, Courand PY, Cautela J, Alexandre J, Procureur A, Rozes A, Leonard-Louis S, Qin J, Akhter N, Aghel N, Amidi K, Anderson E, Arangalage D, Aras M, Asnani A, Baldassarre LA, Barovila R, Barroso AS, Bottinor W, Bouali A, Cariou E, Chang WT, Cheng RK, Crusz SM, Deswal A, Dietrich PY, Dy G, Docq C, Ewer S, Fernando S, Flint DL, Florido R, Fukushima S, Galli E, Gaughan E, Habib M, Haydon A, Heinzerling L, Ben Zadok OI, Issa N, Karlstaedt A, Kitagawa K, Layoun M, Laufer-Perl M, Lenneman C, Leong D, Lesiuk C, Levenson J, López-Fernández T, Liu Y, Machado K, Moliner P, Morimoto R, Obeid M, Narezkina A, Palaskas N, Peretto G, Piriou N, Plana JC, Rainer PP, Robert-Halabi M, Rocher F, Rota E, Roubille F, Ruf T, Sandhu S, Sanjeev F, Seki N, Tajiri K, Tamura Y, Thuny F, Tresorier R, Turker I, Warner E, Zaha V, Zhu H, Cheynier R, Charmeteau-De Muylder B, Redheuil A, Tubach F, Cadranel J, Milon A, Ederhy S, Similowski T, Johnson DB, Pizzo I, Catalan T, Benveniste O, Hayek SS, Allenbach Y, Rosenzwajg M, Dolladille C, Salem JE (2023) Thymus alterations and susceptibility to immune checkpoint inhibitor myocarditis. Nat Med 29:3100–3110. https://doi.org/10.1038/s41591-023-02591-2, DOI: 10.1038/s41591-023-02591-2 35 10.1038/s41591-023-02591-2 false true Reference 55893612 /api/reference/55893612 36. Fernandez DM, Rahman AH, Fernandez NF, Chudnovskiy A, Amir ED, Amadori L, Khan NS, Wong CK, Shamailova R, Hill CA, Wang Z, Remark R, Li JR, Pina C, Faries C, Awad AJ, Moss N, Bjorkegren JLM, Kim-Schulze S, Gnjatic S, Ma’ayan A, Mocco J, Faries P, Merad M, Giannarelli C (2019) Single-cell immune landscape of human atherosclerotic plaques. Nat Med 25:1576–1588. https://doi.org/10.1038/s41591-019-0590-4, DOI: 10.1038/s41591-019-0590-4 36 10.1038/s41591-019-0590-4 false true Reference 55893613 /api/reference/55893613 37. Francis Stuart SD, De Jesus NM, Lindsey ML, Ripplinger CM (2016) The crossroads of inflammation, fibrosis, and arrhythmia following myocardial infarction. J Mol Cell Cardiol 91:114–122. https://doi.org/10.1016/j.yjmcc.2015.12.024, DOI: 10.1016/j.yjmcc.2015.12.024 37 10.1016/j.yjmcc.2015.12.024 false true Reference 55893614 /api/reference/55893614 38. Franco AT, Corken A, Ware J (2015) Platelets at the interface of thrombosis, inflammation, and cancer. Blood 126:582–588. https://doi.org/10.1182/blood-2014-08-531582, DOI: 10.1182/blood-2014-08-531582 38 10.1182/blood-2014-08-531582 false true Reference 55893615 /api/reference/55893615 39. Frostegård J, Ulfgren AK, Nyberg P, Hedin U, Swedenborg J, Andersson U, Hansson GK (1999) Cytokine expression in advanced human atherosclerotic plaques: dominance of pro-inflammatory (Th1) and macrophage-stimulating cytokines. Atherosclerosis 145:33–43. https://doi.org/10.1016/S0021-9150(99)00011-8, DOI: 10.1016/S0021-9150(99)00011-8 39 10.1016/S0021-9150(99)00011-8 false true Reference 55893616 /api/reference/55893616 40. Gergely TG, Drobni ZD, Kallikourdis M, Zhu H, Meijers WC, Neilan TG, Rassaf T, Ferdinandy P, Varga ZV (2024) Immune checkpoints in cardiac physiology and pathology: therapeutic targets for heart failure. Nat Rev Cardiol. https://doi.org/10.1038/s41569-023-00986-9, DOI: 10.1038/s41569-023-00986-9 40 10.1038/s41569-023-00986-9 false true Reference 55893617 /api/reference/55893617 41. Gergely TG, Kucsera D, Tóth VE, Kovács T, Sayour NV, Drobni ZD, Ruppert M, Petrovich B, Ágg B, Onódi Z, Fekete N, Pállinger É, Buzás EI, Yousif LI, Meijers WC, Radovits T, Merkely B, Ferdinandy P, Varga ZV (2022) Characterization of immune checkpoint inhibitor-induced cardiotoxicity reveals interleukin-17A as a driver of cardiac dysfunction after anti-PD-1 treatment. Br J Pharmacol. https://doi.org/10.1111/bph.15984, DOI: 10.1111/bph.15984 41 10.1111/bph.15984 false true Reference 55893618 /api/reference/55893618 42. Gil-Cruz C, Perez-Shibayama C, de Martin A, Ronchi F, van der Borght K, Niederer R, Onder L, Lütge M, Novkovic M, Nindl V, Ramos G, Arnoldini M, Slack EMC, Boivin-Jahns V, Jahns R, Wyss M, Mooser C, Lambrecht BN, Maeder MT, Rickli H, Flatz L, Eriksson U, Geuking MB, McCoy KD, Ludewig B (2019) Microbiota-derived peptide mimics drive lethal inflammatory cardiomyopathy. Science 366:881–886. https://doi.org/10.1126/science.aav3487, DOI: 10.1126/science.aav3487 42 10.1126/science.aav3487 false true Reference 55893619 /api/reference/55893619 43. Gong J, Drobni ZD, Alvi RM, Murphy SP, Sullivan RJ, Hartmann SE, Gilman HK, Lee H, Zubiri L, Raghu VK, Karp-Leaf RS, Zafar A, Zlotoff DA, Frigault MJ, Reynolds KL, Neilan TG (2021) Immune checkpoint inhibitors for cancer and venous thromboembolic events. Eur J Cancer 158:99–110. https://doi.org/10.1016/j.ejca.2021.09.010, DOI: 10.1016/j.ejca.2021.09.010 43 10.1016/j.ejca.2021.09.010 false true Reference 55893620 /api/reference/55893620 44. Gong J, Drobni ZD, Zafar A, Quinaglia T, Hartmann S, Gilman HK, Raghu VK, Gongora C, Sise ME, Alvi RM, Zubiri L, Nohria A, Sullivan R, Reynolds KL, Zlotoff D, Neilan TG (2021) Pericardial disease in patients treated with immune checkpoint inhibitors. J Immunother Cancer 9:1–11. https://doi.org/10.1136/jitc-2021-002771, DOI: 10.1136/jitc-2021-002771 44 10.1136/jitc-2021-002771 false true Reference 55893621 /api/reference/55893621 45. Gong J, Neilan TG, Zlotoff DA (2023) Mediators and mechanisms of immune checkpoint inhibitor-associated myocarditis: Insights from mouse and human. Immunol Rev 318:70–80. https://doi.org/10.1111/imr.13240, DOI: 10.1111/imr.13240 45 10.1111/imr.13240 false true Reference 55893622 /api/reference/55893622 46. Gotsman I, Grabie N, Dacosta R, Sukhova G, Sharpe A, Lichtman AH (2007) Proatherogenic immune responses are regulated by the PD-1/PD-L pathway in mice. J Clin Invest 117:2974–2982. https://doi.org/10.1172/JCI31344, DOI: 10.1172/JCI31344 46 10.1172/JCI31344 false true Reference 55893623 /api/reference/55893623 47. Gotsman I, Lichtman AH (2007) Targeting interferon-γ to treat atherosclerosis. Circ Res 101:333–334. https://doi.org/10.1161/CIRCRESAHA.107.155838, DOI: 10.1161/CIRCRESAHA.107.155838 47 10.1161/CIRCRESAHA.107.155838 false true Reference 55893624 /api/reference/55893624 48. Grainger DJ (2004) Transforming growth factor β and atherosclerosis: so far, so good for the protective cytokine hypothesis. Arterioscler Thromb Vasc Biol 24:399–404. https://doi.org/10.1161/01.ATV.0000114567.76772.33, DOI: 10.1161/01.ATV.0000114567.76772.33 48 10.1161/01.ATV.0000114567.76772.33 false true Reference 55893625 /api/reference/55893625 49. Heinzerling L, Ott PA, Hodi FS, Husain AN, Tajmir-Riahi A, Tawbi H, Pauschinger M, Gajewski TF, Lipson EJ, Luke JJ (2016) Cardiotoxicity associated with CTLA4 and PD1 blocking immunotherapy. J Immunother Cancer. https://doi.org/10.1186/s40425-016-0152-y, DOI: 10.1186/s40425-016-0152-y 49 10.1186/s40425-016-0152-y false true Reference 55893626 /api/reference/55893626 50. Herrmann J (2020) Adverse cardiac effects of cancer therapies: cardiotoxicity and arrhythmia. Nat Rev Cardiol. https://doi.org/10.1038/s41569-020-0348-1, DOI: 10.1038/s41569-020-0348-1 50 10.1038/s41569-020-0348-1 false true Reference 55893627 /api/reference/55893627 51. Heusch G (2023) Cardioprotection in cardio-oncology: a case for concern? Cardiovasc Res 119:E144–E145. https://doi.org/10.1093/cvr/cvad111, DOI: 10.1093/cvr/cvad111 51 10.1093/cvr/cvad111 false true Reference 55893628 /api/reference/55893628 52. Horio Y, Takamatsu K, Tamanoi D, Sato R, Saruwatari K, Ikeda T, Nakane S, Nakajima M, Saeki S, Ichiyasu H, Fujii K, Tomita Y (2018) Trousseau’s syndrome triggered by an immune checkpoint blockade in a non-small cell lung cancer patient. Eur J Immunol 48:1764–1767. https://doi.org/10.1002/eji.201847645, DOI: 10.1002/eji.201847645 52 10.1002/eji.201847645 false true Reference 55893629 /api/reference/55893629 53. Huang YV, Lee D, Sun Y, Chou H, Xu B, Lin Z, Branche C, Bayer A, Waliany S, Neal J, Wakelee H, Witteles R, Nguyen P, Graves E, Alcaide P, Berry GJ, Wu SM, Zhu H (2024) A novel therapeutic approach using CXCR3 blockade to treat immune checkpoint inhibitor-mediated myocarditis. BioRxiv. https://doi.org/10.1101/2024.01.30.576279, DOI: 10.1101/2024.01.30.576279 53 10.1101/2024.01.30.576279 false true Reference 55893630 /api/reference/55893630 54. Hulsmans M, Clauss S, Xiao L, Aguirre AD, King KR, Hanley A, Hucker WJ, Wülfers EM, Seemann G, Courties G, Iwamoto Y, Sun Y, Savol AJ, Sager HB, Lavine KJ, Fishbein GA, Capen DE, Da Silva N, Miquerol L, Wakimoto H, Seidman CE, Seidman JG, Sadreyev RI, Naxerova K, Mitchell RN, Brown D, Libby P, Weissleder R, Swirski FK, Kohl P, Vinegoni C, Milan DJ, Ellinor PT, Nahrendorf M (2017) Macrophages facilitate electrical conduction in the heart. Cell 169:510-522.e20. https://doi.org/10.1016/j.cell.2017.03.050, DOI: 10.1016/j.cell.2017.03.050 54 10.1016/j.cell.2017.03.050 false true Reference 55893631 /api/reference/55893631 55. Inno A, Maurea N, Metro G, Carbone A, Russo A, Gori S (2021) Immune checkpoint inhibitors-associated pericardial disease: a systematic review of case reports. Cancer Immunol Immunother 70:3041–3053. https://doi.org/10.1007/s00262-021-02938-z, DOI: 10.1007/s00262-021-02938-z 55 10.1007/s00262-021-02938-z false true Reference 55893632 /api/reference/55893632 56. Jarr K-U, Nakamoto R, Doan BH, Kojima Y, Weissman IL, Advani RH, Iagaru A, Leeper NJ (2021) Effect of CD47 blockade on vascular inflammation. N Engl J Med 384:382–383. https://doi.org/10.1056/nejmc2029834, DOI: 10.1056/nejmc2029834 56 10.1056/nejmc2029834 false true Reference 55893633 /api/reference/55893633 57. Jiang Z, Sun H, Yu J, Tian W, Song Y (2021) Targeting CD47 for cancer immunotherapy. J Hematol Oncol 14:1–18. https://doi.org/10.1186/s13045-021-01197-w, DOI: 10.1186/s13045-021-01197-w 57 10.1186/s13045-021-01197-w false true Reference 55893634 /api/reference/55893634 58. Johnson DB, Balko JM, Compton ML, Chalkias S, Gorham J, Xu Y, Hicks M, Puzanov I, Alexander MR, Bloomer TL, Becker JR, Slosky DA, Phillips EJ, Pilkinton MA, Craig-Owens L, Kola N, Plautz G, Reshef DS, Deutsch JS, Deering RP, Olenchock BA, Lichtman AH, Roden DM, Seidman CE, Koralnik IJ, Seidman JG, Hoffman RD, Taube JM, Diaz LA, Anders RA, Sosman JA, Moslehi JJ (2016) Fulminant myocarditis with combination immune checkpoint blockade. N Engl J Med 375:1749–1755. https://doi.org/10.1056/nejmoa1609214, DOI: 10.1056/nejmoa1609214 58 10.1056/nejmoa1609214 false true Reference 55893635 /api/reference/55893635 59. Kahnert K, Soattin L, Mills RW, Wilson C, Maurya S, Sorrentino A, Van de Vegte YJ, Hansen FB, Achter J, Hu W, Zi M, Smith M, Van der Harst P, Olesen MS, Olsen KB, Banner J, Jensen THL, Zhang H, Boyett MR, D’Souza A, Lundby A (2024) Proteomics couples electrical remodeling to inflammation in a murine model of heart failure with sinus node dysfunction. Cardiovasc Res 00:1–16. https://doi.org/10.1093/cvr/cvae054, DOI: 10.1093/cvr/cvae054 59 10.1093/cvr/cvae054 false true Reference 55893636 /api/reference/55893636 60. Katsume Y, Isawa T, Toi Y, Fukuda R, Kondo Y, Sugawara S, Ootomo T (2018) Complete atrioventricular block associated with pembrolizumab-induced acute myocarditis: the need for close cardiac monitoring. Intern Med 57:3157–3162. https://doi.org/10.2169/internalmedicine.0255-17, DOI: 10.2169/internalmedicine.0255-17 60 10.2169/internalmedicine.0255-17 false true Reference 55893637 /api/reference/55893637 61. Kyaw T, Winship A, Tay C, Kanellakis P, Hosseini H, Cao A, Li P, Tipping P, Bobik A, Toh BH (2013) Cytotoxic and proinflammatory CD8+ T lymphocytes promote development of vulnerable atherosclerotic plaques in ApoE-deficient mice. Circulation 127:1028–1039. https://doi.org/10.1161/CIRCULATIONAHA.112.001347, DOI: 10.1161/CIRCULATIONAHA.112.001347 61 10.1161/CIRCULATIONAHA.112.001347 false true Reference 55893638 /api/reference/55893638 62. Laenens D, Yu Y, Santens B, Jacobs J, Beuselinck B, Bechter O, Wauters E, Staessen J, Janssens S, Van Aelst L (2022) Incidence of cardiovascular events in patients treated with immune checkpoint inhibitors. J Clin Oncol 40:3430–3438. https://doi.org/10.1200/JCO.21.01808, DOI: 10.1200/JCO.21.01808 62 10.1200/JCO.21.01808 false true Reference 55893639 /api/reference/55893639 63. Langford CA, Cuthbertson D, Ytterberg SR, Khalidi N, Monach PA, Carette S, Seo P, Moreland LW, Weisman M, Koening CL, Sreih AG, Spiera R, McAlear CA, Warrington KJ, Pagnoux C, McKinnon K, Forbess LJ, Hoffman GS, Borchin R, Krischer JP, Merkel PA, Consortium for the VCR (2017) A randomized, double-blind trial of abatacept (CTLA-4Ig) for the treatment of giant cell arteritis. Arthritis Rheumatol 69:837–845. https://doi.org/10.1002/art.40044, DOI: 10.1002/art.40044 63 10.1002/art.40044 false true Reference 55893640 /api/reference/55893640 64. Läubli H, Balmelli C, Bossard M, Pfister O, Glatz K, Zippelius A (2015) Acute heart failure due to autoimmune myocarditis under pembrolizumab treatment for metastatic melanoma. J Immunother Cancer 3:4–9. https://doi.org/10.1186/s40425-015-0057-1, DOI: 10.1186/s40425-015-0057-1 64 10.1186/s40425-015-0057-1 false true Reference 55893641 /api/reference/55893641 65. Laurat E, Poirier B, Tupin E, Caligiuri G, Hansson GK, Bariéty J, Nicoletti A (2001) In vivo downregulation of T helper cell 1 immune responses reduces atherogenesis in apolipoprotein E-knockout mice. Circulation 104:197–202. https://doi.org/10.1161/01.CIR.104.2.197, DOI: 10.1161/01.CIR.104.2.197 65 10.1161/01.CIR.104.2.197 false true Reference 55893642 /api/reference/55893642 66. Lazzerini PE, Laghi-Pasini F, Boutjdir M, Capecchi PL (2022) Inflammatory cytokines and cardiac arrhythmias: the lesson from COVID-19. Nat Rev Immunol 22:270–272. https://doi.org/10.1038/s41577-022-00714-3, DOI: 10.1038/s41577-022-00714-3 66 10.1038/s41577-022-00714-3 false true Reference 55893643 /api/reference/55893643 67. Lee CM, Wang M, Rajkumar A, Calabrese C, Calabrese L (2024) A scoping review of vasculitis as an immune-related adverse event from checkpoint inhibitor therapy of cancer: unraveling the complexities at the intersection of immunology and vascular pathology. Semin Arthritis Rheum 66:152440. https://doi.org/10.1016/j.semarthrit.2024.152440, DOI: 10.1016/j.semarthrit.2024.152440 67 10.1016/j.semarthrit.2024.152440 false true Reference 55893644 /api/reference/55893644 68. Lee J, Zhuang Y, Wei X, Shang F, Wang J, Zhang Y, Liu X, Yang Y, Liu L, Zheng Q (2009) Contributions of PD-1/PD-L1 pathway to interactions of myeloid DCs with T cells in atherosclerosis. J Mol Cell Cardiol 46:169–176. https://doi.org/10.1016/j.yjmcc.2008.10.028, DOI: 10.1016/j.yjmcc.2008.10.028 68 10.1016/j.yjmcc.2008.10.028 false true Reference 55893645 /api/reference/55893645 69. Lehmann LH, Heckmann MB, Bailly G, Finke D, Procureur A, Power JR, Stein F, Bretagne M, Ederhy S, Fenioux C, Hamwy O, Funck-Brentano E, Romano E, Pieroni L, Münster JP, Allenbach Y, Anquetil C, Leonard-Louis S, Palaskas NL, Hayek SS, Katus HA, Giannitsis E, Frey N, Kaya Z, Moslehi J, Prifti E, Salem JE (2023) Cardiomuscular biomarkers in the diagnosis and prognostication of immune checkpoint inhibitor myocarditis. Circulation 148:473–486. https://doi.org/10.1161/CIRCULATIONAHA.123.062405, DOI: 10.1161/CIRCULATIONAHA.123.062405 69 10.1161/CIRCULATIONAHA.123.062405 false true Reference 55893646 /api/reference/55893646 70. Leitinger N, Schulman IG (2013) Phenotypic polarization of macrophages in atherosclerosis. Arterioscler Thromb Vasc Biol 33:1120–1126. https://doi.org/10.1161/ATVBAHA.112.300173, DOI: 10.1161/ATVBAHA.112.300173 70 10.1161/ATVBAHA.112.300173 false true Reference 55893647 /api/reference/55893647 71. Li J (2021) The role of autoantibodies in arrhythmogenesis. Curr Cardiol Rep. https://doi.org/10.1007/s11886-020-01430-x, DOI: 10.1007/s11886-020-01430-x 71 10.1007/s11886-020-01430-x false true Reference 55893648 /api/reference/55893648 72. Libby P (2021) The changing landscape of atherosclerosis. Nature 592:524–533. https://doi.org/10.1038/s41586-021-03392-8, DOI: 10.1038/s41586-021-03392-8 72 10.1038/s41586-021-03392-8 false true Reference 55893649 /api/reference/55893649 73. Da LJ, Nishi H, Poles J, Niu X, Mccauley C, Rahman K, Brown EJ, Yeung ST, Vozhilla N, Weinstock A, Ramsey SA, Fisher EA, Loke P (2019) Single-cell analysis of fate-mapped macrophages reveals heterogeneity, including stem-like properties, during atherosclerosis progression and regression. JCI Insight. https://doi.org/10.1172/jci.insight.124574, DOI: 10.1172/jci.insight.124574 73 10.1172/jci.insight.124574 false true Reference 55893650 /api/reference/55893650 74. Lin J, Li M, Wang Z, He S, Xuming M, Li D (2010) The role of CD4+CD25+ regulatory T cells in macrophage-derived foam-cell formation. J Lipid Res 51:1208–1217. https://doi.org/10.1194/jlr.D000497, DOI: 10.1194/jlr.D000497 74 10.1194/jlr.D000497 false true Reference 55893651 /api/reference/55893651 75. Lintermans LL, Stegeman CA, Heeringa P, Abdulahad WH (2014) T cells in vascular inflammatory diseases. Front Immunol 5:1–12. https://doi.org/10.3389/fimmu.2014.00504, DOI: 10.3389/fimmu.2014.00504 75 10.3389/fimmu.2014.00504 false true Reference 55893652 /api/reference/55893652 76. Lou B, Guo M, Zheng T, Liu J, Wang C, Chen T, Chen F, Fan X, Gao S, Liang X, Qiang H, Li L, Zhou B, Yuan Z, She J (2024) Single-cell RNA sequencing reveals the altered innate immunity in immune checkpoint inhibitor-related myocarditis. Immunology 172:235–251. https://doi.org/10.1111/imm.13770, DOI: 10.1111/imm.13770 76 10.1111/imm.13770 false true Reference 55893653 /api/reference/55893653 77. Lyon AR, López-Fernández T, Couch LS, Asteggiano R, Aznar MC, Bergler-Klein J, Boriani G, Cardinale D, Cordoba R, Cosyns B, Cutter DJ, de Azambuja E, de Boer RA, Dent SF, Farmakis D, Gevaert SA, Gorog DA, Herrmann J, Lenihan D, Moslehi J, Moura B, Salinger SS, Stephens R, Suter TM, Szmit S, Tamargo J, Thavendiranathan P, Tocchetti CG, van der Meer P, van der Pal HJH (2022) 2022 ESC Guidelines on cardio-oncology developed in collaboration with the European Hematology Association (EHA), the European Society for Therapeutic Radiology and Oncology (ESTRO) and the International Cardio-Oncology Society (IC-OS): developed by the task force on cardio-oncology of the European Society of Cardiology (ESC). Eur Heart J 43:4229–4361. https://doi.org/10.1093/eurheartj/ehac244, DOI: 10.1093/eurheartj/ehac244 77 10.1093/eurheartj/ehac244 false true Reference 55893654 /api/reference/55893654 78. Lyon AR, Yousaf N, Battisti NML, Moslehi J, Larkin J (2018) Immune checkpoint inhibitors and cardiovascular toxicity. Lancet Oncol 19:e447–e458. https://doi.org/10.1016/S1470-2045(18)30457-1, DOI: 10.1016/S1470-2045(18)30457-1 78 10.1016/S1470-2045(18)30457-1 false true Reference 55893655 /api/reference/55893655 79. Ma P, Liu J, Qin J, Lai L, Heo GS, Luehmann H, Sultan D, Bredemeyer A, Bajapa G, Feng G, Jimenez J, He R, Parks A, Amrute J, Villanueva A, Liu Y, Lin C-Y, Mack M, Amancherla K, Moslehi J, Lavine KJ (2024) Expansion of pathogenic cardiac macrophages in immune checkpoint inhibitor myocarditis. Circulation 149:48–66. https://doi.org/10.1161/CIRCULATIONAHA.122.062551, DOI: 10.1161/CIRCULATIONAHA.122.062551 79 10.1161/CIRCULATIONAHA.122.062551 false true Reference 55893656 /api/reference/55893656 80. Ma X, Bi E, Lu Y, Su P, Huang C, Liu L, Wang Q, Yang M, Kalady MF, Qian J, Zhang A, Gupte AA, Hamilton DJ, Zheng C, Yi Q (2019) Cholesterol induces CD8+ T cell exhaustion in the tumor microenvironment. Cell Metab 30:143-156.e5. https://doi.org/10.1016/j.cmet.2019.04.002, DOI: 10.1016/j.cmet.2019.04.002 80 10.1016/j.cmet.2019.04.002 false true Reference 55893657 /api/reference/55893657 81. Mahmood SS, Fradley MG, Cohen JV, Nohria A, Reynolds KL, Heinzerling LM, Sullivan RJ, Damrongwatanasuk R, Chen CL, Gupta D, Kirchberger MC, Awadalla M, Hassan MZO, Moslehi JJ, Shah SP, Ganatra S, Thavendiranathan P, Lawrence DP, Groarke JD, Neilan TG (2018) Myocarditis in patients treated with immune checkpoint inhibitors. J Am Coll Cardiol 71:1755–1764. https://doi.org/10.1016/j.jacc.2018.02.037, DOI: 10.1016/j.jacc.2018.02.037 81 10.1016/j.jacc.2018.02.037 false true Reference 55893658 /api/reference/55893658 82. Matsumoto T, Sasaki N, Yamashita T, Emoto T, Kasahara K, Mizoguchi T, Hayashi T, Yodoi K, Kitano N, Saito T, Yamaguchi T, Hirata KI (2016) Overexpression of cytotoxic T-lymphocyte-associated antigen-4 prevents atherosclerosis in mice. Arterioscler Thromb Vasc Biol 36:1141–1151. https://doi.org/10.1161/ATVBAHA.115.306848, DOI: 10.1161/ATVBAHA.115.306848 82 10.1161/ATVBAHA.115.306848 false true Reference 55893659 /api/reference/55893659 83. Michel L, Helfrich I, Hendgen-Cotta UB, Mincu RI, Korste S, Mrotzek SM, Spomer A, Odersky A, Rischpler C, Herrmann K, Umutlu L, Coman C, Ahrends R, Sickmann A, Löffek S, Livingstone E, Ugurel S, Zimmer L, Gunzer M, Schadendorf D, Totzeck M, Rassaf T (2022) Targeting early stages of cardiotoxicity from anti-PD1 immune checkpoint inhibitor therapy. Eur Heart J 43:316–329. https://doi.org/10.1093/eurheartj/ehab430, DOI: 10.1093/eurheartj/ehab430 83 10.1093/eurheartj/ehab430 false true Reference 55893660 /api/reference/55893660 84. Mir H, Alhussein M, Alrashidi S, Alzayer H, Alshatti A, Valettas N, Mukherjee SD, Nair V, Leong DP (2018) Cardiac complications associated with checkpoint inhibition: a systematic review of the literature in an important emerging area. Can J Cardiol 34:1059–1068. https://doi.org/10.1016/j.cjca.2018.03.012, DOI: 10.1016/j.cjca.2018.03.012 84 10.1016/j.cjca.2018.03.012 false true Reference 55893661 /api/reference/55893661 85. Moore KJ, Sheedy FJ, Fisher EA (2013) Macrophages in atherosclerosis: a dynamic balance. Nat Rev Immunol 13:709–721. https://doi.org/10.1038/nri3520, DOI: 10.1038/nri3520 85 10.1038/nri3520 false true Reference 55893662 /api/reference/55893662 86. Moslehi J, Lichtman AH, Sharpe AH, Galluzzi L, Kitsis RN (2021) Immune checkpoint inhibitor-associated myocarditis: Manifestations and mechanisms. J Clin Invest. https://doi.org/10.1172/JCI145186, DOI: 10.1172/JCI145186 86 10.1172/JCI145186 false true Reference 55893663 /api/reference/55893663 87. Mulholland M, Kritikou E, Katra P, Nilsson J, Björkbacka H, Lichtman AH, Rodriguez A, Engelbertsen D (2022) LAG3 regulates T cell activation and plaque infiltration in atherosclerotic mice. JACC CardioOncol 4:635–645. https://doi.org/10.1016/j.jaccao.2022.09.005, DOI: 10.1016/j.jaccao.2022.09.005 87 10.1016/j.jaccao.2022.09.005 false true Reference 55893664 /api/reference/55893664 88. Nishimura H, Okazaki T, Tanaka Y, Nakatani K, Hara M, Matsumori A, Sasayama S, Mizoguchi A, Hiai H, Minato N, Honjo T (2001) Autoimmune dilated cardiomyopathy in PD-1 receptor-deficient mice. Science 291:319–322. https://doi.org/10.1126/science.291.5502.319, DOI: 10.1126/science.291.5502.319 88 10.1126/science.291.5502.319 false true Reference 55893665 /api/reference/55893665 89. Okazaki T, Tanaka Y, Nishio R, Mitsuiye T, Mizoguchi A, Wang J, Ishida M, Hiai H, Matsumori A, Minato N, Honjo T (2003) Autoantibodies against cardiac troponin I are responsible for dilated cardiomyopathy in PD-1-deficient mice. Nat Med 9:1477–1483. https://doi.org/10.1038/nm955, DOI: 10.1038/nm955 89 10.1038/nm955 false true Reference 55893666 /api/reference/55893666 90. Oren O, Yang EH, Molina JR, Bailey KR, Blumenthal RS, Kopecky SL (2020) Cardiovascular health and outcomes in cancer patients receiving immune checkpoint inhibitors. Am J Cardiol 125:1920–1926. https://doi.org/10.1016/j.amjcard.2020.02.016, DOI: 10.1016/j.amjcard.2020.02.016 90 10.1016/j.amjcard.2020.02.016 false true Reference 55893667 /api/reference/55893667 91. Palaskas N, Lopez-Mattei J, Durand JB, Iliescu C, Deswal A (2020) Immune checkpoint inhibitor myocarditis: pathophysiological characteristics, diagnosis, and treatment. J Am Heart Assoc 9:1–12. https://doi.org/10.1161/JAHA.119.013757, DOI: 10.1161/JAHA.119.013757 91 10.1161/JAHA.119.013757 false true Reference 55893668 /api/reference/55893668 92. Palaskas NL, Segura A, Lelenwa L, Siddiqui BA, Subudhi SK, Lopez-Mattei J, Durand JB, Deswal A, Zhao B, Maximilian Buja L, Iliescu C (2021) Immune checkpoint inhibitor myocarditis: elucidating the spectrum of disease through endomyocardial biopsy. Eur J Heart Fail 23:1725–1735. https://doi.org/10.1002/ejhf.2265, DOI: 10.1002/ejhf.2265 92 10.1002/ejhf.2265 false true Reference 55893669 /api/reference/55893669 93. Paulsson G, Zhou X, Törnquist E, Hansson GK (2000) Oligoclonal T cell expansions in atherosclerotic lesions of apolipoprotein E-deficient mice. Arterioscler Thromb Vasc Biol 20:10–17. https://doi.org/10.1161/01.ATV.20.1.10, DOI: 10.1161/01.ATV.20.1.10 93 10.1161/01.ATV.20.1.10 false true Reference 55893670 /api/reference/55893670 94. Pober JS, Tellides G (2012) Participation of blood vessel cells in human adaptive immune responses. Trends Immunol 33:49–57. https://doi.org/10.1016/j.it.2011.09.006, DOI: 10.1016/j.it.2011.09.006 94 10.1016/j.it.2011.09.006 false true Reference 55893671 /api/reference/55893671 95. Poels K, van Leent MMT, Boutros C, Tissot H, Roy S, Meerwaldt AE, Toner YCA, Reiche ME, Kusters PJH, Malinova T, Huveneers S, Kaufman AE, Mani V, Fayad ZA, de Winther MPJ, Marabelle A, Mulder WJM, Robert C, Seijkens TTP, Lutgens E (2020) Immune checkpoint inhibitor therapy aggravates T cell-driven plaque inflammation in atherosclerosis. JACC CardioOncol 2:599–610. https://doi.org/10.1016/j.jaccao.2020.08.007, DOI: 10.1016/j.jaccao.2020.08.007 95 10.1016/j.jaccao.2020.08.007 false true Reference 55893672 /api/reference/55893672 96. Poels K, van Leent MMT, Reiche ME, Kusters PJH, Huveneers S, de Winther MPJ, Mulder WJM, Lutgens E, Seijkens TTP (2020) Antibody-mediated inhibition of CTLA4 aggravates atherosclerotic plaque inflammation and progression in hyperlipidemic mice. Cells. https://doi.org/10.3390/cells9091987, DOI: 10.3390/cells9091987 96 10.3390/cells9091987 false true Reference 55893673 /api/reference/55893673 97. Postow MA, Sidlow R, Hellmann MD (2018) Immune-related adverse events associated with immune checkpoint blockade. N Engl J Med 378:158–168. https://doi.org/10.1056/NEJMra1703481, DOI: 10.1056/NEJMra1703481 97 10.1056/NEJMra1703481 false true Reference 55893674 /api/reference/55893674 98. Quagliariello V, Passariello M, Di Mauro A, Cipullo C, Paccone A, Barbieri A, Palma G, Luciano A, Buccolo S, Bisceglia I, Canale ML, Gallucci G, Inno A, De Lorenzo C, Maurea N (2022) Immune checkpoint inhibitor therapy increases systemic SDF-1, cardiac DAMPs Fibronectin-EDA, S100/Calgranulin, galectine-3, and NLRP3-MyD88-chemokine pathways. Front Cardiovasc Med. https://doi.org/10.3389/fcvm.2022.930797, DOI: 10.3389/fcvm.2022.930797 98 10.3389/fcvm.2022.930797 false true Reference 55893675 /api/reference/55893675 99. Quagliariello V, Passariello M, Rea D, Barbieri A, Iovine M, Bonelli A, Caronna A, Botti G, De Lorenzo C, Maurea N (2020) Evidences of CTLA-4 and PD-1 blocking agents-induced cardiotoxicity in cellular and preclinical models. J Pers Med 10:1–19. https://doi.org/10.3390/jpm10040179, DOI: 10.3390/jpm10040179 99 10.3390/jpm10040179 false true Reference 55893676 /api/reference/55893676 100. Racine JJ, Bachman JF, Zhang J-G, Misherghi A, Khadour R, Kaisar S, Bedard O, Jenkins C, Abbott A, Forte E, Rainer P, Rosenthal N, Sattler S, Serreze DV (2024) Murine MHC-deficient nonobese diabetic mice carrying human HLA-DQ8 develop severe myocarditis and myositis in response to anti–PD-1 immune checkpoint inhibitor cancer therapy. J Immunol 212:1287–1306. https://doi.org/10.4049/jimmunol.2300841, DOI: 10.4049/jimmunol.2300841 100 10.4049/jimmunol.2300841 false true Reference 55893677 /api/reference/55893677 101. Régnier P, Le Joncour A, MacIejewski-Duval A, Darrasse-Jèze G, Dolladille C, Meijers WC, Bastarache L, Fouret P, Bruneval P, Arbaretaz F, Sayetta C, Márquez A, Rosenzwajg M, Klatzmann D, Cacoub P, Moslehi JJ, Salem JE, Saadoun D (2023) CTLA-4 pathway is instrumental in giant cell arteritis. Circ Res 133:298–312. https://doi.org/10.1161/CIRCRESAHA.122.322330, DOI: 10.1161/CIRCRESAHA.122.322330 101 10.1161/CIRCRESAHA.122.322330 false true Reference 55893678 /api/reference/55893678 102. Robertson AKL, Hansson GK (2006) T cells in atherogenesis: for better or for worse? Arterioscler Thromb Vasc Biol 26:2421–2432. https://doi.org/10.1161/01.ATV.0000245830.29764.84, DOI: 10.1161/01.ATV.0000245830.29764.84 102 10.1161/01.ATV.0000245830.29764.84 false true Reference 55893679 /api/reference/55893679 103. Rubio-Infante N, Ramírez-Flores YA, Castillo EC, Lozano O, García-Rivas G, Torre-Amione G (2021) Cardiotoxicity associated with immune checkpoint inhibitor therapy: a meta-analysis. Eur J Heart Fail 23:1739–1747. https://doi.org/10.1002/ejhf.2289, DOI: 10.1002/ejhf.2289 103 10.1002/ejhf.2289 false true Reference 55893680 /api/reference/55893680 104. Salem J-E, Bretagne M, Abbar B, Leonard-Louis S, Ederhy S, Redheuil A, Boussouar S, Nguyen LS, Procureur A, Stein F, Fenioux C, Devos P, Gougis P, Dres M, Demoule A, Psimaras D, Lenglet T, Maisonobe T, De Chambrun MP, Hekimian G, Straus C, Gonzalez-Bermejo J, Klatzmann D, Rigolet A, Guillaume-Jugnot P, Champtiaux N, Benveniste O, Weiss N, Saheb S, Rouvier P, Plu I, Gandjbakhch E, Kerneis M, Hammoudi N, Zahr N, Llontop C, Morelot-Panzini C, Lehmann L, Qin J, Moslehi JJ, Rosenzwajg M, Similowski T, Allenbach Y (2023) Abatacept/ruxolitinib and screening for concomitant respiratory muscle failure to mitigate fatality of immune-checkpoint inhibitor myocarditis. Cancer Discov 13:1100–1115. https://doi.org/10.1158/2159-8290.CD-22-1180, DOI: 10.1158/2159-8290.CD-22-1180 104 10.1158/2159-8290.CD-22-1180 false true Reference 55893681 /api/reference/55893681 105. Salem JE, Manouchehri A, Moey M, Lebrun-Vignes B, Bastarache L, Pariente A, Gobert A, Spano JP, Balko JM, Bonaca MP, Roden DM, Johnson DB, Moslehi JJ (2018) Cardiovascular toxicities associated with immune checkpoint inhibitors: an observational, retrospective, pharmacovigilance study. Lancet Oncol 19:1579–1589. https://doi.org/10.1016/S1470-2045(18)30608-9, DOI: 10.1016/S1470-2045(18)30608-9 105 10.1016/S1470-2045(18)30608-9 false true Reference 55893682 /api/reference/55893682 106. Sato R, Imamura K, Sakata S, Ikeda T, Horio Y, Iyama S, Akaike K, Hamada S, Jodai T, Nakashima K, Ishizuka S, Sato N, Saruwatari K, Saeki S, Tomita Y, Sakagami T (2019) Disorder of coagulation-fibrinolysis system: an emerging toxicity of anti-pd-1/pd-l1 monoclonal antibodies. J Clin Med. https://doi.org/10.3390/jcm8060762, DOI: 10.3390/jcm8060762 106 10.3390/jcm8060762 false true Reference 55893683 /api/reference/55893683 107. Sayour NV, Paál ÁM, Ameri P, Meijers WC, Minotti G, Andreadou I, Lombardo A, Camilli M, Drexel H, Grove EL, Dan GA, Ivanescu A, Semb AG, Savarese G, Dobrev D, Crea F, Kaski J-C, de Boer RA, Ferdinandy P, Varga ZV (2024) Heart failure pharmacotherapy and cancer: pathways and pre-clinical/clinical evidence. Eur Heart J 45:1224–1240. https://doi.org/10.1093/eurheartj/ehae105, DOI: 10.1093/eurheartj/ehae105 107 10.1093/eurheartj/ehae105 false true Reference 55893684 /api/reference/55893684 108. Seijkens TTP, Lutgens E (2018) Cardiovascular oncology: exploring the effects of targeted cancer therapies on atherosclerosis. Curr Opin Lipidol 29(5):381–388, DOI: 10.1097/MOL.0000000000000538 108 10.1097/MOL.0000000000000538 false true Reference 55893685 /api/reference/55893685 109. Shirai T, Hilhorst M, Harrison DG, Goronzy JJ, Weyand CM (2015) Macrophages in vascular inflammation—from atherosclerosis to vasculitis. Autoimmunity 48:139–151. https://doi.org/10.3109/08916934.2015.1027815, DOI: 10.3109/08916934.2015.1027815 109 10.3109/08916934.2015.1027815 false true Reference 55893686 /api/reference/55893686 110. Suero-Abreu GA, Zanni MV, Neilan TG (2022) Atherosclerosis with immune checkpoint inhibitor therapy: evidence, diagnosis, and management: JACC: cardiooncology state-of-the-art review. JACC CardioOncol 4:598–615. https://doi.org/10.1016/j.jaccao.2022.11.011, DOI: 10.1016/j.jaccao.2022.11.011 110 10.1016/j.jaccao.2022.11.011 false true Reference 55893687 /api/reference/55893687 111. Tay WT, Fang YH, Beh ST, Liu YW, Hsu LW, Yen CJ, Liu PY (2020) Programmed cell death-1: programmed cell death-ligand 1 interaction protects human cardiomyocytes against T-cell mediated inflammation and apoptosis response in vitro. Int J Mol Sci. https://doi.org/10.3390/ijms21072399, DOI: 10.3390/ijms21072399 111 10.3390/ijms21072399 false true Reference 55893688 /api/reference/55893688 112. Totzeck M, Schuler M, Stuschke M, Heusch G, Rassaf T (2019) Cardio-oncology—strategies for management of cancer-therapy related cardiovascular disease. Int J Cardiol 280:163–175. https://doi.org/10.1016/j.ijcard.2019.01.038, DOI: 10.1016/j.ijcard.2019.01.038 112 10.1016/j.ijcard.2019.01.038 false true Reference 55893689 /api/reference/55893689 113. Tsuruoka K, Wakabayashi S, Morihara H, Matsunaga N, Fujisaka Y, Goto I, Imagawa A, Asahi M (2020) Exacerbation of autoimmune myocarditis by an immune checkpoint inhibitor is dependent on its time of administration in mice. Int J Cardiol 313:67–75. https://doi.org/10.1016/j.ijcard.2020.04.033, DOI: 10.1016/j.ijcard.2020.04.033 113 10.1016/j.ijcard.2020.04.033 false true Reference 55893690 /api/reference/55893690 114. Vuong JT, Stein-Merlob AF, Nayeri A, Sallam T, Neilan TG, Yang EH (2022) Immune checkpoint therapies and atherosclerosis: mechanisms and clinical implications: JACC state-of-the-art review. J Am Coll Cardiol 79:577–593. https://doi.org/10.1016/j.jacc.2021.11.048, DOI: 10.1016/j.jacc.2021.11.048 114 10.1016/j.jacc.2021.11.048 false true Reference 55893691 /api/reference/55893691 115. Waliany S, Lee D, Witteles RM, Neal JW, Nguyen P, Davis MM, Salem J, Wu SM, Moslehi JJ, Zhu H (2021) Immune checkpoint inhibitor cardiotoxicity: understanding basic mechanisms and clinical characteristics and finding a cure. Annu Rev Pharmacol Toxicol 40:1–22 115 false true Reference 55893692 /api/reference/55893692 116. Webster RM (2014) The immune checkpoint inhibitors: where are we now? Nat Rev Drug Discov 13:883–884. https://doi.org/10.1038/nrd4476, DOI: 10.1038/nrd4476 116 10.1038/nrd4476 false true Reference 55893693 /api/reference/55893693 117. Wei SC, Meijers WC, Axelrod ML, Anang NAAS, Screever EM, Wescott EC, Johnson DB, Whitley E, Lehmann L, Courand PY, Mancuso JJ, Himmel LE, Lebrun-Vignes B, Wleklinski MJ, Knollmann BC, Srinivasan J, Li Y, Atolagbe OT, Rao X, Zhao Y, Wang J, Ehrlich LIR, Sharma P, Salem JE, Balko JM, Moslehi JJ, Allison JP (2021) A genetic mouse model recapitulates immune checkpoint inhibitor–associated myocarditis and supports a mechanism-based therapeutic intervention. Cancer Discov 11:614–625. https://doi.org/10.1158/2159-8290.CD-20-0856, DOI: 10.1158/2159-8290.CD-20-0856 117 10.1158/2159-8290.CD-20-0856 false true Reference 55893694 /api/reference/55893694 118. Winkels H, Ehinger E, Vassallo M, Buscher K, Dinh HQ, Kobiyama K, Hamers AAJ, Cochain C, Vafadarnejad E, Saliba AE, Zernecke A, Pramod AB, Ghosh AK, Michel NA, Hoppe N, Hilgendorf I, Zirlik A, Hedrick CC, Ley K, Wolf D (2018) Atlas of the immune cell repertoire in mouse atherosclerosis defined by single-cell RNA-sequencing and mass cytometry. Circ Res 122:1675–1688. https://doi.org/10.1161/CIRCRESAHA.117.312513, DOI: 10.1161/CIRCRESAHA.117.312513 118 10.1161/CIRCRESAHA.117.312513 false true Reference 55893695 /api/reference/55893695 119. Winkels H, Wolf D (2021) Heterogeneity of T cells in atherosclerosis defined by single-cell RNA-sequencing and cytometry by time of flight. Arterioscler Thromb Vasc Biol 41:549–563. https://doi.org/10.1161/ATVBAHA.120.312137, DOI: 10.1161/ATVBAHA.120.312137 119 10.1161/ATVBAHA.120.312137 false true Reference 55893696 /api/reference/55893696 120. Won T, Kalinoski HM, Wood MK, Hughes DM, Jaime CM, Delgado P, Talor MV, Lasrado N, Reddy J, Čiháková D (2022) Cardiac myosin-specific autoimmune T cells contribute to immune-checkpoint-inhibitor-associated myocarditis. Cell Rep. https://doi.org/10.1016/j.celrep.2022.111611, DOI: 10.1016/j.celrep.2022.111611 120 10.1016/j.celrep.2022.111611 false true Reference 55893697 /api/reference/55893697 121. Xia W, Zou C, Chen H, Xie C, Hou M (2020) Immune checkpoint inhibitor induces cardiac injury through polarizing macrophages via modulating microRNA-34a/Kruppel-like factor 4 signaling. Cell Death Dis. https://doi.org/10.1038/s41419-020-02778-2, DOI: 10.1038/s41419-020-02778-2 121 10.1038/s41419-020-02778-2 false true Reference 55893698 /api/reference/55893698 122. Yang M, Cao H, Wang C, Yu C, Sun P (2024) Incidence of thromboembolic events in non-small cell lung cancer patients treated with immune checkpoint inhibitors: a systematic review and meta-analysis. J Cancer Res Ther 20(2):509–521, DOI: 10.4103/jcrt.jcrt_1031_23 122 10.4103/jcrt.jcrt_1031_23 false true Reference 55893699 /api/reference/55893699 123. Yu J, Long B, Li Z, Tian X, Li D, Long J, Wang YJ, Chen Y, Zhang F, Liu H, Qian C, Shan J (2024) Central memory CD4+ T cells play a protective role against immune checkpoint inhibitor-associated myocarditis. Cardiovasc Res. https://doi.org/10.1093/cvr/cvae133, DOI: 10.1093/cvr/cvae133 123 10.1093/cvr/cvae133 false true Reference 55893700 /api/reference/55893700 124. Zhang H, Watanabe R, Berry GJ, Vaglio A, Liao YJ, Warrington KJ, Goronzy JJ, Weyand CM (2017) Immunoinhibitory checkpoint deficiency in medium & large vessel vasculitis. Proc Natl Acad Sci U S A 114:E970–E979. https://doi.org/10.1073/pnas.1616848114, DOI: 10.1073/pnas.1616848114 124 10.1073/pnas.1616848114 false true Reference 55893701 /api/reference/55893701 125. Zhang Y, Sun C, Li Y, Qin J, Amancherla K, Jing Y, Hu Q, Liang K, Zhang Z, Ye Y, Huang LA, Nguyen TK, Egranov SD, Zhao Z, Wu A, Xi Y, Yao J, Hung MC, Calin GA, Cheng J, Lim B, Lehmann LH, Salem JE, Johnson DB, Curran MA, Yu D, Han L, Darabi R, Yang L, Moslehi JJ, Lin C (2022) Hormonal therapies up-regulate MANF and overcome female susceptibility to immune checkpoint inhibitor myocarditis. Sci Transl Med 14:1–16. https://doi.org/10.1126/scitranslmed.abo1981, DOI: 10.1126/scitranslmed.abo1981 125 10.1126/scitranslmed.abo1981 false true Reference 55893702 /api/reference/55893702 126. Zhu H, Galdos FX, Lee D, Waliany S, Huang YV, Ryan J, Dang K, Neal JW, Wakelee HA, Reddy SA, Srinivas S, Lin L-L, Witteles RM, Maecker HT, Davis MM, Nguyen PK, Wu SM (2022) Identification of pathogenic immune cell subsets associated with checkpoint inhibitor-induced myocarditis. Circulation 146:316–335. https://doi.org/10.1161/CIRCULATIONAHA.121.056730, DOI: 10.1161/CIRCULATIONAHA.121.056730 126 10.1161/CIRCULATIONAHA.121.056730 false true Reference 55893703 /api/reference/55893703 127. Zlotoff DA, Hassan MZO, Zafar A, Alvi RM, Awadalla M, Mahmood SS, Zhang L, Chen CL, Ederhy S, Barac A, Banerji D, Jones-O’connor M, Murphy SP, Armanious M, Forrestal BJ, Kirchberger MC, Coelho-Filho OR, Rizvi MA, Sahni G, Mandawat A, Tocchetti CG, Hartmann S, Gilman HK, Zatarain-Nicolás E, Mahmoudi M, Gupta D, Sullivan R, Ganatra S, Yang EH, Heinzerling LM, Thuny F, Zubiri L, Reynolds KL, Cohen JV, Lyon AR, Groarke J, Thavendiranathan P, Nohria A, Fradley MG, Neilan TG (2021) Electrocardiographic features of immune checkpoint inhibitor associated myocarditis. J Immunother Cancer 9:1–10. https://doi.org/10.1136/jitc-2020-002007, DOI: 10.1136/jitc-2020-002007 127 10.1136/jitc-2020-002007 false true /api/publication/35140697 Gergely Tamás G. et al. Molecular fingerprints of cardiovascular toxicities of immune checkpoint inhibitors. (2025) BASIC RESEARCH IN CARDIOLOGY 0300-8428 1435-1803 120 1 187-205<div class="JournalArticle Publication long-list"> <div class="authors"> <img title="Forrásközlemény" style="float: left" src="/frontend/resources/grid/publication-core-icon.png"> <img title="Idézőközlemény" style="float: left" src="/frontend/resources/grid/publication-citation-icon.png"> <div class="autype autype0"> <a href="/gui2/?type=authors&mode=browse&sel=10074629" target="_blank">Gergely Tamás G. (Gergely Tamás G kardiovaszkuláris farmakológia) </a> SU/FM/I/Department of Pharmacology and Pharmacotherapy; SU/FM/I/DPP/HCEMM-SU Cardiometabolic Immunology Research Group; SU/FM/I/DPP/MTA-SE Momentum Cardio-Oncology and Cardioimmunology Research Group; SU/KSZE/Centre for Pharmacology and Pharmaceutical Research Development ;    <a href="/gui2/?type=authors&mode=browse&sel=10061268" target="_blank">Drobni Zsófia D. (Drobni Zsófia kardiológia) </a> SU/FM/C/Cardiovascular Center; SU/FM/C/Cardiovascular Center/Department of Cardiology – Heart and Vascular Center ;    <a href="/gui2/?type=authors&mode=browse&sel=10074459" target="_blank">Sayour Nabil V. (Sayour Viktor Nabil farmakológia) </a> SU/FM/I/Department of Pharmacology and Pharmacotherapy; SU/FM/I/DPP/HCEMM-SU Cardiometabolic Immunology Research Group; SU/FM/I/DPP/MTA-SE Momentum Cardio-Oncology and Cardioimmunology Research Group; SU/KSZE/Centre for Pharmacology and Pharmaceutical Research Development ;    <a href="/gui2/?type=authors&mode=browse&sel=10010125" target="_blank">Ferdinandy Péter (Ferdinandy Péter Farmakológia, molekuláris medicina) </a> SU/FM/I/Department of Pharmacology and Pharmacotherapy; SU/KSZE/Centre for Pharmacology and Pharmaceutical Research Development ;    <a href="/gui2/?type=authors&mode=browse&sel=10028393" target="_blank">Varga Zoltán V. ✉ (Varga Zoltán kardiovaszkuláris kutatás) </a> SU/FM/I/Department of Pharmacology and Pharmacotherapy; SU/FM/I/DPP/HCEMM-SU Cardiometabolic Immunology Research Group; SU/FM/I/DPP/MTA-SE Momentum Cardio-Oncology and Cardioimmunology Research Group; SU/KSZE/Centre for Pharmacology and Pharmaceutical Research Development </div> </div> <div class="title"><a href="/gui2/?mode=browse&params=publication;35140697" target="_blank">Molecular fingerprints of cardiovascular toxicities of immune checkpoint inhibitors</a></div> <div> BASIC RESEARCH IN CARDIOLOGY (<a target="_blank" href="https://portal.issn.org/resource/ISSN/0300-8428">0300-8428</a> <a target="_blank" href="https://portal.issn.org/resource/ISSN/1435-1803">1435-1803</a>): 120 1 pp 187-205 (2025) </div> <div class="pub-footer"> Language: English | <a style="color:blue" title="10.1007/s00395-024-01068-8" target="_blank" href="https://doi.org/10.1007/s00395-024-01068-8"> DOI </a> <a style="color:blue" title="001271499300001" target="_blank" href="https://www.webofscience.com/wos/woscc/full-record/001271499300001"> WoS </a> <a style="color:blue" title="85198939587" target="_blank" href="http://www.scopus.com/record/display.url?origin=inward&eid=2-s2.0-85198939587"> Scopus </a> <a style="color:blue" title="39023770" target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=39023770&dopt=Abstract"> PubMed </a> <a style="color:blue" title="https://www.scopus.com/inward/record.uri?eid=2-s2.0-85198939587&doi=10.1007%2Fs00395-024-01068-8&partnerID=40&md5=cd8fad35ee84a0cdbb8d5e6799041fca" target="_blank" href="https://www.scopus.com/inward/record.uri?eid=2-s2.0-85198939587&doi=10.1007%2Fs00395-024-01068-8&partnerID=40&md5=cd8fad35ee84a0cdbb8d5e6799041fca"> Other URL </a> <a style="color:blue" title="https://link.springer.com/10.1007/s00395-024-01068-8" target="_blank" href="https://link.springer.com/10.1007/s00395-024-01068-8"> Other URL </a> <OnlyViewableByAuthor><div class="ratings"> <div class="journal-subject">Journal subject: Scopus - Cardiology and Cardiovascular Medicine   Rank: D1</div> <div class="journal-subject">Journal subject: Scopus - Physiology (medical)   Rank: D1</div> <div class="journal-subject">Journal subject: Scopus - Physiology   Rank: D1</div> </div></OnlyViewableByAuthor> <div class="publication-citation" style="margin-left: 0.5cm;"> Citing papers: 32 | Independent citation: 31 | Self citation: 1 | Unknown citation: 0 | Number of citations in WoS: 31 | Number of citations in Scopus: 29 | WoS/Scopus assigned: 32 | Number of citations with DOI: 32 </div> <div class="publication-citation"> <a target="_blank" href="/api/publication?cond=citations.related;eq;35140697&sort=publishedYear,desc&sort=title"> Number of cited publications: 9 </a> </div> <div class="mtid">Publication: 35140697 | Validated Core Citing | Journal Article ( Survey paper ) | Scientific | kézi felvitel </div> <div class="funder"> (Open access funding provided by Semmelweis University), HCEMM(739593) Funder: Horizon 2020, (LP-2021-14), (RRF-2.3.1-21-2022-00003), (2022-1.1.1-KK-2022-00005), Az orvos-, egészségtudományi- és gyógyszerészképzés tudományos műhelyeinek fejlesztése(EFOP-3.6.3-VEKOP-16-2017-00009) Funder: EFOP-VEKOP, (Semmelweis 250+ Excellence Scholarship), Richter Gedeon Talentum Foundation, (ÚNKP-22-4-II-SE), (ÚNKP-23-II-SE-43) </div> <div class="lastModified">Last Modified: 2026.02.24. 13:55 Márta Molnár-Taga (SE 4-es admin) </div> <pre class="comment" style="margin-top: 0; margin-bottom: 0;">Comments: Export Date: 09 April 2025; Cited By: 5; CODEN: BRCAB</pre> </div></div>